<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6438">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01768403</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-CDZ-XXX-2012/1</org_study_id>
    <nct_id>NCT01768403</nct_id>
  </id_info>
  <brief_title>Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia</brief_title>
  <acronym>CEPHEUS</acronym>
  <official_title>Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>Algeria: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Centralized Pan-Algerian Survey on the undertreatment of hypercholesterolemia. The purpose
      of this study is to establish the proportion of patients on lipid-lowering pharmacological
      treatment reaching the LDL-C goals according to the Third Joint European Task Force
      guidelines in the survey population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Centralised Pan-Algerian Survey on the undertreatment of hypercholesterolemia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Number and percentage of subjects achieving the LDL-C goals, according to the Third Joint European Task Force (TJETF) guidelines.</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects achieving LDL-C goals according to the TJETF guidelines.</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>In the following sub-populations: - Patients with / or not with metabolic syndrome (according to NCEP III definition), - Primary/secondary prevention patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects achieving LDL-C goals according to the NCEP ATP III/2004 updated NCEP ATP III and to the 2005 AFSSAPS guidelines</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall and in the following sub-populations: Patients with/or without metabolic syndrome-Iary/IIary preven</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects achieving LDL-C goals according to the : TJETF / NCEP ATP III and 2004 updated NCEP ATP III guidelines.</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>For the following sub-populations: Demographic variables, CV risk factors &amp; Lipid-lowering agent class</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The association between achievement of LDL-C goals, according to the Third Joint European Task Force / NCEP ATP III / 2004 updated NCEP ATP III guidelines, and patient and physician variables, assessed by multivariate logistic regression models</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1236</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Hypertension</condition>
  <condition>Diabetes</condition>
  <condition>Coronary Heart Disease</condition>
  <condition>Peripheral Arterial Disease</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  Subject must be 19 years of age or older of either gender or race.

          -  Subject must provide informed consent and comply with the survey procedures.

          -  Subject is on lipid lowering drug treatment for at least 3 months, with no dose
             change for a minimum of 6 weeks
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must provide informed consent and comply with the survey procedures.

          -  Subject is on lipid lowering drug treatment for at least 3 months, with no dose
             change for a minimum of 6 weeks.

        Exclusion Criteria:

        - Subjects who are unwilling or unable to provide informed consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Habib BENNACEUR, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nawel BOUTEKDJIRET, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yassin BOUHOUITA-GUERMECH, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology department /Mustapha Bacha Hospital</affiliation>
  </overall_official>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 14, 2013</lastchanged_date>
  <firstreceived_date>January 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Coronary Heart disease</keyword>
  <keyword>Peripheral Arterial disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
